This study evaluated urinary epithelial cell adhesion molecule (EpCAM), normalised to urinary creatinine, as a noninvasive biomarker for identifying clinically significant prostate cancer (csPCa) in men with equivocal PSA levels.<h4>Methods</h4>This cross-sectional study included 286 men with PSA levels of 4-10 ng/mL scheduled for prostate biopsy. This evidence concerns the gene EPCAM and prostate carcinoma.